As of 19 June 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of the following health technologies for possible government financing: These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by the DOH, such as the DOH Omnibus Health Guidelines (OHG); and/or international, but locally continue reading : HTA Council Preliminary Recommendation on Tuberculosis Diagnostic Tests
HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
Update as of 18 June 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on these health technologies ended on 10 June 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted on 18 June 2025 to the Secretary of Health, pending decision. As of 26 continue reading : HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
Update as of 26 May 2025 : The public consultation and appeals period for the HTA Council Preliminary Recommendation on Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diphtheria, and pertussis for Grade 1 students (6-7 years old), Grade 7 students (11-12 years old) and pregnant women ended on 19 May 2025. Having received continue reading : HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
Update as of 14 May 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children ended on 13 May 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final continue reading : HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
HTA Council Preliminary Recommendation on Coagulation Factor VIII and Factor VIII Inhibitor Bypassing Activity
Update as of 29 April 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Coagulation Factor VIII and Factor VIII Inhibitor Bypassing Activity ended on 25 April 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of Health on 29 April continue reading : HTA Council Preliminary Recommendation on Coagulation Factor VIII and Factor VIII Inhibitor Bypassing Activity